Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models

Marilia Barreca, Arribas, Olivier P. Thomas, Francesco Bertoni, Filippo Spriano, Jennings, Miguel-Gordo, O'Brien

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphomas, accounting for 30%-40% of new cases each year. Despite the big improvements achieved in the treatment, still 25–40% of patients still succumb due to refractory or relapsed disease. This highlights the need of new drugs for this cancer. The marine environment has recentlybeen recognized as a source of anti-cancer compounds, as demonstrated by different marine drugs approved by different regulatory agencies (trabectedin, cytarabine, eribulin, plitidepsin) or as components of antibody drugconjugates for lymphoma patients (monomethyl auristatin E in polatuzumab vedotin and brentuximab vedotin). Here, we present a large screening of fractions obtained from different marine invertebrates collected in Ireland andin the Pacific Ocean on DLBCL cell lines
Original languageEnglish
Pages (from-to)17-17
Number of pages1
JournalEuropean Journal of Cancer
Volume138
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models'. Together they form a unique fingerprint.

Cite this